Reports and Releases
Change in FIT Biotech’s Management Team
Company Release, September 14.9, 2015 at 16:00 EET
Change in FIT Biotech's Management Team
FIT Biotech Ltd (NASDAQ: FITBIO), a Finnish biotechnology company, announced at the end of July the appointment of Adjunct Professor Milla Koistinaho, Ph.D. to the new position of Chief Operating Officer. The parties have mutually agreed on the termination of the employment relationship . Koistinaho will leave her position as of the date of this announcement.
FIT BIOTECH OY
Board of Directors
CEO Kalevi Reijonen, FIT Biotech Oy
Phone: +358 40 843 5695
Certified Advisor: Translink Corporate Finance Oy, tel. +358 20 743 2790
FIT Biotech Oy in brief:
FIT Biotech Oy is a biotechnology company established in 1995, focusing on DNA vaccines and gene therapy. The company bases its products on its patented GTU ® (Gene Transport Unit) technology. Through GTU technology, FIT Biotech develops DNA vaccines in order to both prevent and also treat various diseases. Identified application areas include HIV, tuberculosis (and other infectious diseases) as well as gene therapy (cancer, autoimmune diseases). Other application areas are under development. FIT Biotech Oy is listed on NASDAQ First North (ticker: FITBIO). More information can be found at www.fitbiotech.com.
NASDAQ OMX Helsinki